H J Muller

Summary

Country: Germany

Publications

  1. ncbi Use of L-asparaginase in childhood ALL
    H J Muller
    Abteilung für Pädiatrische Hämatologie, Munster, Deutschland
    Crit Rev Oncol Hematol 28:97-113. 1998
  2. ncbi Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols
    H J Muller
    Department of Paediatric Haematology Oncology, University of Munster, Germany
    Br J Haematol 110:379-84. 2000
  3. ncbi Pharmacokinetics of native Escherichia coli asparaginase (Asparaginase medac) and hypersensitivity reactions in ALL-BFM 95 reinduction treatment
    H J Muller
    Department of Paediatric Haematology Oncology, University of Munster, Germany
    Br J Haematol 114:794-9. 2001

Collaborators

Detail Information

Publications3

  1. ncbi Use of L-asparaginase in childhood ALL
    H J Muller
    Abteilung für Pädiatrische Hämatologie, Munster, Deutschland
    Crit Rev Oncol Hematol 28:97-113. 1998
    ..abstract truncated)..
  2. ncbi Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols
    H J Muller
    Department of Paediatric Haematology Oncology, University of Munster, Germany
    Br J Haematol 110:379-84. 2000
    ..Substituting 4 x 10,000 U/m2 asparaginase medac for one dose of 1,000 U/m2 Oncaspar was safe and well tolerated. Comparable pharmacokinetic treatment intensity was achieved in about two-thirds of patients...
  3. ncbi Pharmacokinetics of native Escherichia coli asparaginase (Asparaginase medac) and hypersensitivity reactions in ALL-BFM 95 reinduction treatment
    H J Muller
    Department of Paediatric Haematology Oncology, University of Munster, Germany
    Br J Haematol 114:794-9. 2001
    ..Activity in the therapeutic range of greater than 100 U/l for at least 14 d was determined in 43 of the 45 patients who were analysed for enzyme activity...